Sickle Cell Disease Market | DelveInsight
What is Sickle
Cell Disease?
 |
| Sickle Cell Disease market |
How much
population is affected by Sickle Cell Disease?
Sickle cell
disease is irreversible that affects males and females equally, and is
responsible for increased morbidity and mortality in affected persons.
 |
| Sickle Cell Disease prevalance |
There were
approximately 133,385 Sickle Cell Disease prevalent cases in 2017 in the 6MM.
As per DelveInsight, the United
States reports for the highest Sickle Cell Disease prevalent population due to
a large number of immigrants from African countries per year, followed by the
EU5. Among the European countries, France has the highest Sickle Cell Disease
prevalent population with around 15,000 cases followed by the United Kingdom,
which has a Sickle Cell Disease prevalent population around 13,000 in 2017.
Spain has the lowest Sickle Cell Disease prevalent population. Also, it was
found that there is no Sickle Cell Disease prevalence in Japan since the
disease does not occur in the Japanese population.
Which types of
drugs are used in Sickle cell disease treatment?
Most of the
Sickle Cell Disease treatments are dominated by the off label and off-patent
medications (HU; Iron Chelators, Analgesics, Antibiotics, vaccines), to address
the complications or for specific Sickle Cell Disease symptoms.
Hydroxyurea
was the first-ever drug approved for the Sickle Cell Disease treatment in 1998.
However, there is increasing evidence that Hydroxyurea is only prescribed to a
fraction of patients who may be benefited from it. The most distressing issue
with Hydroxyurea was the lack of FDA approval for infants with Sickle Cell
Disease in the United States. However, various trials are undergoing to assess
the safety and efficacy of Hydroxyurea in children. At present, it is used
off-label for pediatric patients.
Sickle Cell
Disease market size was majorly dependent on the use of Hydroxyurea until 2017
when Endari was launched. It was the first drug new drug for sickle cell
patients in nearly two decades and was the first FDA- approved Sickle Cell
Disease treatment for pediatric as well as adult patients.
The approval
of the Emmaus’s Endari for Sickle Cell Disease treatment in the United States
in 2017. It had marked a significant advancement in Sickle Cell Disease
treatment and is expected to pave the way for the development and approval of
additional therapies.
However, the
current therapies used to prevent the complications of the disease are limited,
vary in their effectiveness and are associated with severe risks and
tolerability issues. Besides this, the disease presents with significant unmet
medical needs, with no disease-modifying Sickle Cell Disease treatment for an
ongoing painful crisis.
Thus, new
approaches for Sickle Cell Disease treatment, including new medications,
advances in transplantation, and gene therapies are being explored, which are
expected to significantly drive the Sickle
Cell Disease treatment market during the forecast period.
How many
companies are developing drugs for Sickle Cell Disease?
 |
| Key pharma players in Sickle Cell Disease market |
The companies
across the globe, such as GBT Therapeutics, Pfizer, Novartis, AstraZeneca,
Ironwood Pharmaceuticals, Imara Therapeutics and many others that are involved
in developing therapies for Sickle Cell Disease. The expected launch of
emerging therapies, such as Voxelotor/ GBT-440 (GBT Therapeutics), Rivipansel
(Pfizer), Crizanlizumab (Novartis), IMR-687 (Imara Therapeutics) and other
compelling treatments are expected to increase the Sickle Cell Disease market
size in upcoming years.
Water Hack Burns 2lb of Fat OVERNIGHT
ReplyDeleteAt least 160000 men and women are using a easy and secret "water hack" to drop 2lbs every night as they sleep.
It is scientific and it works all the time.
You can do it yourself by following these easy steps:
1) Take a drinking glass and fill it up half glass
2) Then learn this amazing hack
and you'll become 2lbs skinnier when you wake up!